Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 17Thoracic 3Endocrine 3Gastrointestinal 2Sarcoma 1NET 1Lymphoid 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 317Carcinoma, Non-Small-Cell Lung 72Skin Neoplasms 65Carcinoma, Renal Cell 48Lung Neoplasms 45Breast Neoplasms 45Colorectal Neoplasms 42Carcinoma, Basal Cell 41Neoplasms 40Neoplasm Metastasis 40Squamous Cell Carcinoma of Head and Neck 36Uveal Melanoma 33Ovarian Neoplasms 33Carcinoma, Merkel Cell 32Sarcoma 31Lymphoma, T-Cell, Cutaneous 31Pancreatic Neoplasms 26Prostatic Neoplasms 24Head and Neck Neoplasms 22Stomach Neoplasms 21Thyroid Neoplasms 20Urinary Bladder Neoplasms 19Carcinoma, Hepatocellular 19Uterine Cervical Neoplasms 18Esophageal Neoplasms 18Carcinoma, Squamous Cell 18Mycosis Fungoides 16Carcinoma, Transitional Cell 16Brain Neoplasms 16Recurrence 15

Interventions

binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Diseases × Dermatologic × 90 days × Clear all
NCT04913285 2026-04-27

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Pierre Fabre Medicament

Phase 1 Active not recruiting
400 enrolled
DermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Thyroid Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡